Cure8 research brief
This paper explores whether individualized integrative management including traditional Chinese medicine might influence outcomes in patients with biologic‑refractory, surgery‑intended acute severe ulcerative colitis — a group with limited options where avoiding colectomy would be meaningful.
The findings are preliminary and not definitive.
Clinicians and researchers interested in integrative therapies, IBD specialists managing biologic‑refractory ASUC, and patients on biologics considering alternative or adjunctive treatments.
This small single-centre retrospective case series (39 patients) reports clinical courses for biologic‑refractory, surgery‑intended acute severe ulcerative colitis (ASUC) patients managed with individualised integrative care that included traditional Chinese medicine (TCM).
Eleven patients received adjunctive preoperative TCM; five selected patients achieved endoscopic improvement (Mayo endoscopic subscore fell from 3 to 0–1) and avoided planned surgery, while six TCM patients proceeded to surgery and were compared descriptively with 28 non‑TCM surgical patients.
The study found numerically fewer 30‑day postoperative complications and shorter length of stay in the small TCM surgical group, and lower exploratory inflammatory markers (POD1 WBC, POD3 CRP), but confidence intervals were wide and included the null.
Major baseline imbalances between groups, heterogeneous concomitant treatments, and non‑randomised selection mean these observations are descriptive and hypothesis‑generating only. If you read the paper: look for detailed methods on how TCM was individualised, exact concomitant medical treatments, and the criteria used to cancel surgery.
The authors explicitly caution against interpreting these data as evidence that TCM prevents surgery or improves outcomes.
This is a small, retrospective, non‑randomised case series with major baseline imbalances and heterogeneous treatments; results are descriptive and cannot establish efficacy or causation. The structured content depth is based on the article abstract and available full‑text; findings should be viewed as hypothesis‑generating.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
The trial tests two low-cost adjuncts — a Lactobacillus probiotic and a multi–trace-element supplement — added to biologic-based standard care to see if they help maintain remission in ulcerative colitis. If effective,...
